1:00 PM ET | noon CT | 11:00 AM MT | 10:00 AM PT
In October 2022, Roche/Genentech shared with us plans to initiate a new trial called MANOEUVRE. This global Phase 2 clinical study will evaluate GYM329 (RO7204239), an investigational anti-myostatin antibody targeting muscle growth, in individuals living with FSHD (NCT05548556). We have invited them to share with us, in this upcoming webinar, more about Roche/Genentech, the investigational drug being tested, the design of the trial, and who may be eligible to participate.
Renata Scalco, MD PhD, is the Global Development Leader for GYM329 in FSHD. As Global Development Leader, Renata is responsible for leading a broad team of scientists and experts who work in developing potential new therapies for rare diseases.
Dr. Scalco is a neurologist with experience in treating patients with neuromuscular diseases. She completed a PhD in translational research studies in muscle disorders at the Queen Square, University College London, United Kingdom. Since she joined Roche in 2018 she greatly contributed to risdiplam development in spinal muscular atrophy (SMA).
Louisa Townson is the Global Patient Partnerships leader for FSHD and SMA. The Global Patient Partnership team at Roche works to embed patient perspectives and insights into core decision-making across the company – where Louisa works closely with FSHD patient organizations to ensure their feedback shape Roche’s work in FSHD – including the design of clinical trials. Louisa has been with Roche for 7 years now, supporting clinical development in a range of rare diseases, including many years focusing on neuromuscular conditions including SMA, DMD and ALS. Prior to Roche, she completed a PhD in neuropharmacology at University College London.
Register below for your personalized link to join this webinar.